Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151201 | 1.00 | MPI (0.34) | MPITSHR | |
| Mannose 6-Phosphate SCHEMBL8205373 | 0.88 | MPI (0.55) | MPI | |
| SCHEMBL17844292 | 0.87 | GAA (0.30) | — | |
| SCHEMBL4274441 | 0.86 | TSHR (0.50) | MPITSHR | |
| SCHEMBL4271272 | 0.86 | TSHR (0.50) | MPITSHR | |
| SCHEMBL2722436 | 0.86 | TSHR (0.50) | MPITSHR | |
| SCHEMBL1163840 | 0.86 | TSHR (0.50) | MPITSHR | |
| SCHEMBL4277422 | 0.86 | TSHR (0.50) | MPITSHR | |
| SCHEMBL4268327 | 0.86 | TSHR (0.50) | MPITSHR | |
| SCHEMBL1163588 | 0.86 | TSHR (0.50) | MPITSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241957-A1 | INTRA-ERYTHROCYTE DEXAMETHASONE FOR TREATMENT OF ATAXIA-TELANGIECTASIA | QUINCE THERAPEUTICS S.P.A. (IT) | 2025-07-31 | — | — | US | claimed |
| US-12311059-B2 | Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes | QUINCE THERAPEUTICS S.P.A. (IT) | 2025-05-27 | — | — | US | claimed |
| CN-122038284-A | Method for inducing differentiation of anterior foregut endoderm cells to form lung progenitor cells and application thereof | 广州国家实验室 | 2026-05-15 | — | — | CN | disclosed |
| CN-122038274-A | Method for inducing differentiation and maturation of alveolar organoids and application thereof | 广州国家实验室 | 2026-05-15 | — | — | CN | disclosed |
| US-20260130895-A1 | METABOLISM ENHANCING COMPOSITIONS | Red Mountain Med Spa, LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12551470-B2 | Metabolism enhancing compositions | Red Mountain Med Spa, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-12522854-B2 | Systems, devices and methods for determining most probable number in biological sample analysis | ANCERA, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250325702-A1 | COMPOSITIONS AND METHODS FOR EDITING A TRANSTHYRETIN GENE | BEAM THERAPEUTICS INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4452275-B1 | COMBINATION OF CISPLATIN AND ELIMUSERTIB FOR THE TREATMENT OF PEDIATRIC LIVER CANCERS | INST NAT SANTE RECH MED (FR) | 2025-10-01 | — | — | EP | disclosed |
| US-20250250637-A1 | METHODS AND SYSTEMS FOR IMMUNOME PROFILING FOR CANCER DIAGNOSIS AND TREATMENT PROGNOSIS | TAN, BO (CA) | 2025-08-07 | — | — | US | disclosed |
| US-20250241957-A1 | INTRA-ERYTHROCYTE DEXAMETHASONE FOR TREATMENT OF ATAXIA-TELANGIECTASIA | QUINCE THERAPEUTICS S.P.A. (IT) | 2025-07-31 | — | — | US | disclosed |
| WO-2012085183-A1 | NOVEL BACTERIUM AND EXTRACTS OF SAID BACTERIUM AND THE USE OF SAME IN THERAPY | PIERRE FABRE DERMO-COSMETIQUE (FR) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012040499-A2 | METABOLIC INHIBITORS | SURFACE LOGIX, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20100304450-A1 | MICROBIAL PRODUCTION OF PYRUVATE AND PYRUVATE DERIVATIVES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20060286665-A1 | System for sustained microbial production of hydrogen gas in a bioreactor utilizing an equalization tank | DIZ HARRY R | 2006-12-21 | — | — | US | disclosed |
| WO-1992021234-A1 | COMPOSITION AND METHOD FOR CULTURING AND FREEZING CELLS AND TISSUES | VETREPHARM, INC. (CA) | 1992-12-10 | — | — | WO | disclosed |
| EP-0337003-B1 | USE OF FRUCTOSE-1,6-DIPHOSPHATE IN THE TREATMENT OF ACUTE ALCOHOLIC INTOXICATION AND CHRONIC ETHYLISM, AND RELATED PHARMACEUTICAL COMPOSITIONS | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1992-09-30 | — | — | EP | disclosed |
| US-5102783-A | Using hyaluronic acid acid | VETREPHARM, INC. (CA) | 1992-04-07 | — | — | US | disclosed |
| EP-0337003-A2 | Use of fructose-1,6-diphosphate in the treatment of acute alcoholic intoxication and chronic ethylism, and related pharmaceutical compositions | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1989-10-18 | — | — | EP | disclosed |
| US-4870057-A | Use of fructose-1,6-diphosphate in the treatment of acute alcoholic intoxication and chronic ethylism, and related pharmaceutical compositions | BIOMEDICA FOSCAMA INDUSTRIA CHIMICO-FARMACEUTICA S.P.A. (IT) | 1989-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325702-A1 | COMPOSITIONS AND METHODS FOR EDITING A TRANSTHYRETIN GENE | TTR, TTN, HTT | MPI 2260/4885TSHR 586/4885 |
| US-20260130895-A1 | METABOLISM ENHANCING COMPOSITIONS | GYS2, SLC19A1, SLC19A2 | MPI 530/4885TSHR 3277/4885 |
| US-12551470-B2 | Metabolism enhancing compositions | BHMT, SLC19A2, GYS2 | MPI 755/4885TSHR 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.